Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Merck KGaA drops xevinapant with ph. 3 trial headed for failure
An interim analysis has concluded that Merck KGaA's TrilynX study is unlikely to meet its primary objective of prolonging event-free survival.
James Waldron
Jun 25, 2024 8:50am
Merck KGaA taps AI-focused biotech for new ADC pact worth $376M
Jun 4, 2024 9:45am
Merck KGaA rolls out ‘all-in-one’ CHO genetic stability assay
Apr 18, 2024 4:05pm
Merck KGaA signs $1.4B biobuck ADC deal with Caris
Apr 4, 2024 8:25am
Merck KGaA drops evobrutinib in wake of double phase 3 fail
Mar 7, 2024 9:54am
Merck KGaA paying $16M to join C4's protein degrader hunt
Mar 4, 2024 10:18am
